174 related articles for article (PubMed ID: 24913674)
1. PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[α]indene Derivative in Lung Cancer Cells.
Sanjiv K; Chen CW; Kakadiya R; Tala S; Suman S; Wu MH; Chen YH; Su TL; Lee TC
Transl Oncol; 2014 Apr; 7(2):256-266.e5. PubMed ID: 24913674
[TBL] [Abstract][Full Text] [Related]
2. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.
Lee PC; Kakadiya R; Su TL; Lee TC
Neoplasia; 2010 May; 12(5):376-87. PubMed ID: 20454509
[TBL] [Abstract][Full Text] [Related]
3. The novel DNA alkylating agent BO-1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models.
Sanjiv K; Su TL; Suman S; Kakadiya R; Lai TC; Wang HY; Hsiao M; Lee TC
Int J Cancer; 2012 Mar; 130(6):1440-50. PubMed ID: 21500194
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of autophagy enhances DNA damage-induced apoptosis by disrupting CHK1-dependent S phase arrest.
Liou JS; Wu YC; Yen WY; Tang YS; Kakadiya RB; Su TL; Yih LH
Toxicol Appl Pharmacol; 2014 Aug; 278(3):249-58. PubMed ID: 24823293
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum to "PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[α]indene Derivative in Lung Cancer Cells [Translational Oncology 7 (2014) 256-266.e5].
Sanjiv K; Chen CW; Kakadiya R; Tala S; Suman S; Wu MH; Chen YH; Su TL; Lee TC
Transl Oncol; 2017 Apr; 10(2):295-296. PubMed ID: 28292510
[No Abstract] [Full Text] [Related]
6. Multidrug-resistant cells overexpressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src/nuclear EGFR cascade-activated DNA repair activity.
Lee PC; Lee HJ; Kakadiya R; Sanjiv K; Su TL; Lee TC
Oncogene; 2013 Feb; 32(9):1144-54. PubMed ID: 22525278
[TBL] [Abstract][Full Text] [Related]
7. A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non-Small Cell Lung Cancer Cells.
Chen CW; Wu MH; Chen YF; Yen TY; Lin YW; Chao SH; Tala S; Tsai TH; Su TL; Lee TC
Neoplasia; 2016 Apr; 18(4):199-212. PubMed ID: 27108383
[TBL] [Abstract][Full Text] [Related]
8. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
Friedmann B; Caplin M; Hartley JA; Hochhauser D
Clin Cancer Res; 2004 Oct; 10(19):6476-86. PubMed ID: 15475435
[TBL] [Abstract][Full Text] [Related]
9. BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.
Ambati SR; Shieh JH; Pera B; Lopes EC; Chaudhry A; Wong EW; Saxena A; Su TL; Moore MA
Oncotarget; 2016 Jul; 7(28):43062-43075. PubMed ID: 27248664
[TBL] [Abstract][Full Text] [Related]
10. Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
Kakadiya R; Dong H; Lee PC; Kapuriya N; Zhang X; Chou TC; Lee TC; Kapuriya K; Shah A; Su TL
Bioorg Med Chem; 2009 Aug; 17(15):5614-26. PubMed ID: 19576785
[TBL] [Abstract][Full Text] [Related]
11. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
Yoshioka T; Yogosawa S; Yamada T; Kitawaki J; Sakai T
Gynecol Oncol; 2013 May; 129(2):425-32. PubMed ID: 23403163
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
13. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
Fujiwara M; Izuishi K; Sano T; Hossain MA; Kimura S; Masaki T; Suzuki Y
J Exp Clin Cancer Res; 2008 Nov; 27(1):76. PubMed ID: 19032736
[TBL] [Abstract][Full Text] [Related]
14. Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition.
Fuhrman CB; Kilgore J; LaCoursiere YD; Lee CM; Milash BA; Soisson AP; Zempolich KA
Gynecol Oncol; 2008 Jul; 110(1):93-8. PubMed ID: 18589211
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
[TBL] [Abstract][Full Text] [Related]
16. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
Cancer Res; 2003 Jul; 63(14):4044-7. PubMed ID: 12874004
[TBL] [Abstract][Full Text] [Related]
17. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
Liu Y; Cui B; Qiao Y; Zhang Y; Tian Y; Jiang J; Ma D; Kong B
Int J Gynecol Cancer; 2011 Jan; 21(1):100-5. PubMed ID: 21330835
[TBL] [Abstract][Full Text] [Related]
18. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
Gupta AK; Cerniglia GJ; Mick R; Ahmed MS; Bakanauskas VJ; Muschel RJ; McKenna WG
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):846-53. PubMed ID: 12788194
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
[TBL] [Abstract][Full Text] [Related]
20. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
